---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Rituximab - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/rituximab
version: v1
---

# Rituximab - NCI

# Rituximab

Placeholder slot

(rih-TUK-sih-mab)

This page contains brief information about rituximab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Riabni
Rituxan
Ruxience
Truxima

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563&audience=consumer)

## Use in Cancer

Rituximab is approved to be used alone or with other drugs to treat:

- **[B-cell](/Common/PopUps/popDefinition.aspx?id=444967&version=Patient&language=English) [acute leukemia](/Common/PopUps/popDefinition.aspx?id=45145&version=Patient&language=English)** that is [advanced](/Common/PopUps/popDefinition.aspx?id=478743&version=Patient&language=English) and [CD20](/Common/PopUps/popDefinition.aspx?id=721294&version=Patient&language=English) [positive](/Common/PopUps/popDefinition.aspx?id=44710&version=Patient&language=English). Rituximab is used with [chemotherapy](/Common/PopUps/popDefinition.aspx?id=45214&version=Patient&language=English) in children aged 6 months and older whose cancer has not been treated. This use is approved for the Rituxan brand of rituximab.
- **B-cell [non-Hodgkin lymphoma](/Common/PopUps/popDefinition.aspx?id=45148&version=Patient&language=English)** (NHL) that is CD20 positive. Rituximab is used:
- alone in adults with [follicular lymphoma](/Common/PopUps/popDefinition.aspx?id=428287&version=Patient&language=English) or [low-grade lymphoma](/Common/PopUps/popDefinition.aspx?id=45757&version=Patient&language=English) that has [relapsed](/Common/PopUps/popDefinition.aspx?id=45866&version=Patient&language=English) or is [refractory](/Common/PopUps/popDefinition.aspx?id=45863&version=Patient&language=English) (doesnâ€™t respond to treatment)
- with [first-line](/Common/PopUps/popDefinition.aspx?id=346494&version=Patient&language=English) chemotherapy in adults whose NHL has not been treated
- alone as [maintenance therapy](/Common/PopUps/popDefinition.aspx?id=45768&version=Patient&language=English) in adults who are having a [complete](/Common/PopUps/popDefinition.aspx?id=45652&version=Patient&language=English) or [partial response](/Common/PopUps/popDefinition.aspx?id=45819&version=Patient&language=English) to rituximab and chemotherapy
- alone in adults with [low-grade](/Common/PopUps/popDefinition.aspx?id=45757&version=Patient&language=English) NHL that has not progressed after first-line therapy with [cyclophosphamide](/Common/PopUps/popDefinition.aspx?id=45253&version=Patient&language=English), [vincristine sulfate](/Common/PopUps/popDefinition.aspx?id=615324&version=Patient&language=English), and [prednisone](/Common/PopUps/popDefinition.aspx?id=45492&version=Patient&language=English) ([CVP](/Common/PopUps/popDefinition.aspx?id=662466&version=Patient&language=English))
- with [anthracycline](/Common/PopUps/popDefinition.aspx?id=44916&version=Patient&language=English) [combination chemotherapy](/Common/PopUps/popDefinition.aspx?id=45650&version=Patient&language=English) in adults with [diffuse large B-cell](/Common/PopUps/popDefinition.aspx?id=428286&version=Patient&language=English) NHL (DLBCL) that has not been treated
- with chemotherapy in children aged 6 months and older with DLBCL or [Burkitt lymphoma](/Common/PopUps/popDefinition.aspx?id=45203&version=Patient&language=English) that is advanced and has not been treated

Use in adults is approved for the Riabni, Rituxan, Ruxience, and Truxima brands of rituximab. Use in children is approved for the Rituxan brand of rituximab.

- **[Chronic lymphocytic leukemia](/Common/PopUps/popDefinition.aspx?id=44846&version=Patient&language=English)** (CLL) that is CD20 positive. Rituximab is used with [fludarabine phosphate](/Common/PopUps/popDefinition.aspx?id=613209&version=Patient&language=English) and cyclophosphamide in adults. This use is approved for the Riabni, Rituxan, Ruxience, and Truxima brands of rituximab.

Rituximab is also being studied in the treatment of other conditions and types of cancer.

Rituximab is also available in a different form, combined with [hyaluronidase](/Common/PopUps/popDefinition.aspx?id=791166&version=Patient&language=English). For more information, see the Drug Information Summary for [Rituximab and Hyaluronidase Human](/about-cancer/treatment/drugs/rituximabandhyaluronidasehuman).

## More About Rituximab

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/42613) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Rituximab](https://medlineplus.gov/druginfo/meds/a607038.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Rituximab](https://www.cancer.gov/research/participate/clinical-trials/intervention/C1702) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
